All sponsors

Nanjing Chia-tai Tianqing Pharmaceutical

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING0
READOUTS ≤12 MONTHS3
Open Nanjing Chia-tai Tianqing Pharmaceutical on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
NTQ5082 100mg qd
NCT06764303
P2Active, not recruitingParoxysmal Nocturnal Hemoglobinuria242025-07-08 (+1 mo)
NTQ5082 capsules 100 mg
NCT06982040
P2Not yet recruitingPrimary IgA Nephropathy802026-09
NTQ5082 capsules 200 mg
NCT07177859
P3Not yet recruitingParoxysmal Nocturnal Hemoglobinuria782026-11
Ramelteon
NCT06512363
P3Not yet recruitingChronic Insomnia2802026-12
NTB003
NCT07462130
P1/2Not yet recruitingThyroid Eye Disease742027-05-31
NTQ5082 capsules 200 mg
NCT07177872
P3Not yet recruitingParoxysmal Nocturnal Hemoglobinuria782028-06
NTQ1062+Fulvestrant
NCT07393321
P3Not yet recruitingHR Positive/HER2 Negative Advanced or Metastatic Breast Cancer2102028-08-31